ResearchNew EULAR Data Support CIMZIA Response Regardless of RF Status in RA New EULAR Data Support CIMZIA Response Regardless of RF Status in RA Read Post »
Clinical TrialsLundbeck’s PACAP Inhibitor Bocunebart Meets Endpoint in Migraine Lundbeck’s PACAP Inhibitor Bocunebart Meets Endpoint in Migraine Read Post »
Clinical TrialsBayer’s Finerenone Delivers Positive Phase III Results in Non-Diabeti... Bayer’s Finerenone Delivers Positive Phase III Results in Non-Diabeti... Read Post »
New Drug ApprovalMHRA Approves First MASH Treatment for Patients With Liver Fibrosis MHRA Approves First MASH Treatment for Patients With Liver Fibrosis Read Post »
Clinical TrialsCosentyx Improves Long-Term Disease Control in Polymyalgia Rheumatica Cosentyx Improves Long-Term Disease Control in Polymyalgia Rheumatica Read Post »
Clinical TrialsAutobahn Posts Positive Data for Elunetirom in Bipolar Depression Autobahn Posts Positive Data for Elunetirom in Bipolar Depression Read Post »
Clinical TrialsInnovent Files China NDA for Arcotatug Tavatecan in Advanced Gastric Cancer Innovent Files China NDA for Arcotatug Tavatecan in Advanced Gastric Cancer Read Post »
Clinical TrialsNovartis Reports Positive Final Phase III Results for Vanrafia in IgA Nephr... Novartis Reports Positive Final Phase III Results for Vanrafia in IgA Nephr... Read Post »
Clinical TrialsImmutep Reports Positive Phase I Results for IMP761 in Autoimmune Disease Immutep Reports Positive Phase I Results for IMP761 in Autoimmune Disease Read Post »
Clinical TrialsJohnson & Johnson Reports Positive Phase 2 Lupus Data for Nipocalimab Johnson & Johnson Reports Positive Phase 2 Lupus Data for Nipocalimab Read Post »
Clinical Trialsargenx Shows Durable Efgartigimod Benefits in Myositis and Sjögren’s Dis... argenx Shows Durable Efgartigimod Benefits in Myositis and Sjögren’s Dis... Read Post »
Clinical TrialsTenaya’s TN-201 Shows Durable Benefits in MYBPC3-Associated HCM Tenaya’s TN-201 Shows Durable Benefits in MYBPC3-Associated HCM Read Post »
Clinical TrialsUCB Shows Long-Term Benefits of BIMZELX in PsA and axSpA UCB Shows Long-Term Benefits of BIMZELX in PsA and axSpA Read Post »
Clinical TrialsTakeda, Innovent Advance IBI363 With Strong Survival Data in Resistant NSCL... Takeda, Innovent Advance IBI363 With Strong Survival Data in Resistant NSCL... Read Post »
Clinical TrialsCelcuity’s Gedatolisib Delivers Strong Phase 3 Win in Advanced Breast... Celcuity’s Gedatolisib Delivers Strong Phase 3 Win in Advanced Breast... Read Post »
Clinical TrialsAbivax’s Obefazimod Meets All Phase 3 Endpoints in Ulcerative Colitis Abivax’s Obefazimod Meets All Phase 3 Endpoints in Ulcerative Colitis Read Post »
Clinical TrialsIDEAYA Scores Registrational Win for Darovasertib in Metastatic Uveal Melan... IDEAYA Scores Registrational Win for Darovasertib in Metastatic Uveal Melan... Read Post »
Clinical TrialsAstraZeneca’s Camizestrant Extends Progression-Free Survival in SERENA-6 AstraZeneca’s Camizestrant Extends Progression-Free Survival in SERENA-6 Read Post »
Clinical TrialsIza-bren Extends Survival in Phase 3 Trials Across Triple-Negative Breast a... Iza-bren Extends Survival in Phase 3 Trials Across Triple-Negative Breast a... Read Post »
Clinical TrialsEntrada Advances ENTR-601-45 to Higher Dose Cohort in DMD Entrada Advances ENTR-601-45 to Higher Dose Cohort in DMD Read Post »
New Drug ApprovalAbbVie Secures EU Approval for AQUIPTA in Acute Migraine AbbVie Secures EU Approval for AQUIPTA in Acute Migraine Read Post »
New Drug ApprovalAmgen Wins EU Approval for IMDYLLTRA in Relapsed ES-SCLC Amgen Wins EU Approval for IMDYLLTRA in Relapsed ES-SCLC Read Post »
Clinical TrialsIdorsia Reports Positive High-Dose Phase 1 Data for C. difficile Vaccine Idorsia Reports Positive High-Dose Phase 1 Data for C. difficile Vaccine Read Post »
Clinical TrialsPersonalized mRNA Vaccine Plus KEYTRUDA Maintains Strong Melanoma Outcomes Personalized mRNA Vaccine Plus KEYTRUDA Maintains Strong Melanoma Outcomes Read Post »
Clinical TrialsIdorsia Unveils New Phase 3 Evidence for Aprocitentan’s Renal Benefits Idorsia Unveils New Phase 3 Evidence for Aprocitentan’s Renal Benefits Read Post »
Clinical TrialsNovartis Reports Strong Three-Year Scemblix Results in Newly Diagnosed CML Novartis Reports Strong Three-Year Scemblix Results in Newly Diagnosed CML Read Post »
New Drug ApprovalShionogi Wins FDA Approval for First Oral XOCOVA to Prevent COVID-19 After ... Shionogi Wins FDA Approval for First Oral XOCOVA to Prevent COVID-19 After ... Read Post »
Clinical TrialsBioNTech and BMS Report Strong Phase 2 Activity for Pumitamig in NSCLC BioNTech and BMS Report Strong Phase 2 Activity for Pumitamig in NSCLC Read Post »
Clinical TrialsReplimune’s RP2 Shows Durable Responses in Advanced Solid Tumors Replimune’s RP2 Shows Durable Responses in Advanced Solid Tumors Read Post »
Clinical TrialsASCO 2026: Novartis’s New PSMAddition Analysis Supports Broad Pluvicto Us... ASCO 2026: Novartis’s New PSMAddition Analysis Supports Broad Pluvicto Us... Read Post »
Clinical TrialsLilly’s Retevmo Reduces Recurrence Risk by 83% in RET-Positive NSCLC Lilly’s Retevmo Reduces Recurrence Risk by 83% in RET-Positive NSCLC Read Post »
Clinical TrialsAkeso’s Ivonescimab Cuts Risk of Death by 34% in Phase 3 Squamous NSCLC T... Akeso’s Ivonescimab Cuts Risk of Death by 34% in Phase 3 Squamous NSCLC T... Read Post »
Clinical TrialsApalutamide Plus ADT Delivers Landmark Phase 3 Results in High‑Risk Local... Apalutamide Plus ADT Delivers Landmark Phase 3 Results in High‑Risk Local... Read Post »
Clinical TrialsCogent’s PEAK Trial Shows Significant Survival Benefit in KIT-Driven GIST Cogent’s PEAK Trial Shows Significant Survival Benefit in KIT-Driven GIST Read Post »
Clinical TrialsIncyte’s frontMIND Trial Delivers Positive Phase 3 Results in High-Risk D... Incyte’s frontMIND Trial Delivers Positive Phase 3 Results in High-Risk D... Read Post »
Clinical TrialsPfizer’s TALAPRO-3 Trial Shows Strong Benefit for TALZENNA Plus XTAND... Pfizer’s TALAPRO-3 Trial Shows Strong Benefit for TALZENNA Plus XTAND... Read Post »
Clinical TrialsImmunome’s Varegacestat Cuts Risk of Desmoid Tumor Progression by 84% in ... Immunome’s Varegacestat Cuts Risk of Desmoid Tumor Progression by 84% in ... Read Post »
Clinical TrialsFirst-Line RYBREVANT Plus LAZCLUZE Shows Sustained Survival in Atypical EGF... First-Line RYBREVANT Plus LAZCLUZE Shows Sustained Survival in Atypical EGF... Read Post »
New Drug ApprovalFDA Approves First Inhaled Mealtime Insulin for Pediatric Diabetes FDA Approves First Inhaled Mealtime Insulin for Pediatric Diabetes Read Post »
Clinical TrialsDizal’s Sunvozertinib Outperforms Chemotherapy in WU-KONG28 Trial Dizal’s Sunvozertinib Outperforms Chemotherapy in WU-KONG28 Trial Read Post »
New Drug ApprovalFDA Approves Wockhardt’s ZAYNICH; India Also Grants Authorization FDA Approves Wockhardt’s ZAYNICH; India Also Grants Authorization Read Post »
Clinical TrialsPfizer Reports Landmark Seven-Year Results for LORBRENA in ALK-Positive NSC... Pfizer Reports Landmark Seven-Year Results for LORBRENA in ALK-Positive NSC... Read Post »
Clinical TrialsAstraZeneca’s Anselamimab Shows Survival Benefit in Kappa AL Amyloidosis,... AstraZeneca’s Anselamimab Shows Survival Benefit in Kappa AL Amyloidosis,... Read Post »
New Drug ApprovalEuropean Commission Authorizes New VENCLYXTO Regimens for CLL European Commission Authorizes New VENCLYXTO Regimens for CLL Read Post »
Clinical TrialsMajesTEC‑9 Confirms TECVAYLI Survival Benefit in Relapsed Multiple Myelom... MajesTEC‑9 Confirms TECVAYLI Survival Benefit in Relapsed Multiple Myelom... Read Post »
Clinical TrialsFDA Updates TREMFYA Label With Structural Joint Damage Data in PsA FDA Updates TREMFYA Label With Structural Joint Damage Data in PsA Read Post »
New Drug ApprovalImfinzi Cuts Recurrence Risk by 32% and Wins FDA Approval in High-Risk NMIB... Imfinzi Cuts Recurrence Risk by 32% and Wins FDA Approval in High-Risk NMIB... Read Post »
Clinical TrialsFDA Prioritizes Review of Zydus’ Saroglitazar for Rare Liver Disease FDA Prioritizes Review of Zydus’ Saroglitazar for Rare Liver Disease Read Post »
Clinical TrialsZanidatamab–Tislelizumab Triplet Delivers Practice‑Changing Survival Ga... Zanidatamab–Tislelizumab Triplet Delivers Practice‑Changing Survival Ga... Read Post »
Clinical TrialsNervGen Reports Neural Recovery Signals With NVG-291 in Chronic SCI Trial NervGen Reports Neural Recovery Signals With NVG-291 in Chronic SCI Trial Read Post »
